Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Letrozole|DRUG: Everolimus|DRUG: TRC105
Sponsor: University of Alabama at Birmingham
Collaborators: Novartis Pharmaceuticals|Tracon Pharmaceuticals Inc.